Journal of Pulmonology and Respiratory Diseases
Open Access

Lung cancer; Immunotherapy; Immune checkpoint inhibitors; T-cell therapy; Tumor microenvironment; Personalized medicine; Oncolytic viruses; Cancer vaccines.

Introduction

Lung cancer, particularly non-small cell lung cancer (NSCLC), remains one of the deadliest cancers globally, accounting for over 1.8 million deaths each year. Despite advancements in surgical techniques, chemotherapy, and radiation therapy, prognosis for advanced lung cancer remains poor. Over the past decade, immunotherapy has emerged as a revolutionary approach, offering new hope for patients who were previously limited to palliative care or toxic chemotherapies [1 ,2]. Immunotherapy works by harnessing the body's immune system to fight cancer, potentially offering longer-lasting effects and fewer side effects than traditional therapies. This article explores the most significant advancements in lung cancer immunotherapy, providing a comprehensive review of current therapeutic strategies, clinical successes, challenges, and the future potential of immunotherapeutic interventions.

Current immunotherapy strategies in lung cancer

Immune checkpoint inhibitors

The introduction of immune checkpoint inhibitors has marked the most notable breakthrough in lung cancer treatment. These inhibitors work by blocking the "brakes" on the immune system that cancer cells exploit to avoid immune detection [3,4]. The most prominent immune checkpoints involved in NSCLC treatment are the Programmed cell death protein 1 (PD-1) receptor and its ligand, PD-L1, as well as Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). PD-1/PD-L1 Inhibitors: Drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) block the PD-1 receptor on T-cells, preventing the interaction between PD-1 and PD-L1, which is expressed by tumor cells. This interaction normally inhibits immune response, and its blockade restores the immune system’s ability to detect and destroy cancer cells. These drugs have shown remarkable success in patients with advanced NSCLC, leading to increased survival rates and durable responses in a subset of patients. CTLA-4 Inhibitors: Ipilimumab (Yervoy) is a monoclonal antibody that blocks CTLA-4, another checkpoint protein that suppresses T-cell activation [5,6]. Though its use in NSCLC is less widespread than PD-1/PD-L1 inhibitors, it has demonstrated clinical efficacy when combined with PD-1 inhibitors. These checkpoint inhibitors are now standard treatment for patients with metastatic or advanced NSCLC and have shown a significant improvement in overall survival compared to traditional chemotherapy.

Cancer vaccines

Cancer vaccines aim to stimulate the immune system to recognize and target tumor-specific antigens, leading to the elimination of cancer cells. While not yet as established as immune checkpoint inhibitors, cancer vaccines have shown promise in early-stage clinical trials. Therapeutic Vaccines: These vaccines are designed to treat existing cancer by stimulating the immune system to target tumor-associated antigens. The most well-known example in lung cancer research is the MAGE-A3 vaccine, which targets the MAGE-A3 protein expressed in some NSCLC tumors [7]. While initial trials were disappointing, ongoing studies are exploring ways to enhance the efficacy of such vaccines. Preventive Vaccines: The development of vaccines for the prevention of lung cancer, similar to how the human papillomavirus (HPV) vaccine prevents cervical cancer, is also an exciting frontier. However, such vaccines are still in early phases of research and development.

Adoptive T-cell therapy

Adoptive T-cell therapy involves the extraction of T-cells from a patient’s blood, their expansion or genetic modification in a laboratory to enhance their cancer-fighting properties, and their reinfusion into the patient. This approach has shown some success in other cancers, including melanoma, and is under active investigation in lung cancer [8]. Chimeric Antigen Receptor T-cell Therapy (CAR-T) While CAR-T therapies have revolutionized the treatment of hematologic cancers, their application in solid tumors, including lung cancer, remains challenging. The unique tumor microenvironment of solid tumors and issues related to T-cell infiltration and persistence limit the current success of CAR-T therapy in lung cancer. However, ongoing research is focusing on overcoming these obstacles by modifying the CAR-T cells to enhance their ability to target lung cancer cells.

Oncolytic virus therapy

Oncolytic virus therapy uses genetically modified viruses that selectively infect and kill cancer cells while sparing normal cells. These viruses can also stimulate an immune response against the tumor [9]. Early-stage clinical trials have shown promising results in NSCLC, with viruses like T-VEC (talimogene laherparepvec) being explored for their potential to treat lung cancer. While the therapeutic potential is promising, the challenge lies in optimizing the viral delivery systems, ensuring tumor specificity, and overcoming the immune responses that may neutralize the viruses before they can have an effect.

Emerging approaches and challenges in immunotherapy

Personalized immunotherapy

One of the most exciting developments in lung cancer immunotherapy is the move toward personalized medicine. The concept of tailoring treatments based on the genetic and molecular characteristics of an individual’s tumor holds significant promise [10]. Molecular profiling of NSCLC tumors allows the identification of mutations and alterations that may predict responses to specific immunotherapies. Tumor Mutational Burden (TMB)  TMB is a measure of the number of mutations within the tumor genome. High TMB has been associated with better responses to immune checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors. Personalized treatment strategies based on TMB and other biomarkers are being tested in clinical trials and may soon become standard practice. PD-L1 Expression: While PD-L1 expression on tumor cells is a critical biomarker for predicting response to PD-1 inhibitors, not all patients with high PD-L1 expression respond to treatment. Thus, there is an ongoing need for additional biomarkers that can better predict who will benefit from immunotherapy.

Combination therapies

Combination therapies have the potential to enhance the effectiveness of immunotherapy. The combination of immune checkpoint inhibitors with other treatments, such as chemotherapy, targeted therapies, or radiation, has shown promise in preclinical studies and early clinical trials.

Chemotherapy and Immunotherapy: Combining chemotherapy with immunotherapy has become a common strategy for advanced NSCLC. Chemotherapy can increase the immunogenicity of tumor cells, making them more susceptible to immune attack, while checkpoint inhibitors help sustain the immune response.

Targeted Therapy and Immunotherapy: Targeted therapies, such as EGFR inhibitors or ALK inhibitors, have shown efficacy in patients with specific mutations. Combining these therapies with immune checkpoint inhibitors may provide synergistic effects, especially in tumors with high mutational burden.

Tumor microenvironment and resistance

The tumor microenvironment plays a significant role in shaping the immune response to cancer. Immunosuppressive factors within the tumor, such as regulatory T-cells, myeloid-derived suppressor cells, and other immune checkpoint molecules, can hinder the effectiveness of immunotherapy. A deeper understanding of the tumor microenvironment is crucial for developing strategies to overcome resistance to immunotherapy and enhance therapeutic outcomes. Resistance to immune checkpoint inhibitors, either intrinsic or acquired, remains a major challenge. Researchers are investigating how to overcome resistance by targeting the immune microenvironment, utilizing novel checkpoint inhibitors, or combining therapies that modulate the immune response.

Future directions

The future of lung cancer immunotherapy is exciting, with numerous ongoing studies and clinical trials. Some promising future directions include

Improved biomarkers: The development of more accurate and comprehensive biomarkers will be essential to predict patient responses to immunotherapy.

Next-generation immunotherapies: The development of novel immune modulators, such as immune adjuvants, T-cell engagers, and bispecific antibodies, could significantly enhance the efficacy of current treatments.

Combination with novel therapeutics: As we learn more about the genetic and immune landscape of lung cancer, the combination of immunotherapy with personalized medicine, targeted therapies, and novel agents will likely improve patient outcomes.

Gene editing and immunotherapy: The use of CRISPR and other gene-editing technologies to modify immune cells, making them more effective against cancer cells, is an area of active research that holds great potential for lung cancer immunotherapy.

Conclusion

Lung cancer immunotherapy has made tremendous progress in recent years, transforming the treatment paradigm for patients with advanced NSCLC. Immune checkpoint inhibitors have become standard treatment for many patients, and the development of new immunotherapeutic strategies continues to evolve. As we move forward, personalized approaches, combination therapies, and overcoming challenges related to tumor resistance and the microenvironment will be key to improving outcomes. With continued research and clinical advancements, immunotherapy has the potential to significantly extend survival and improve quality of life for patients with lung cancer.

1. Mello RD, Dickenson AH (2008) Spinal cord mechanisms of pain. BJA 101: 8-16.

Indexed at, Google Scholar, Crossref

2. Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, et al (2000) A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthr Cartil 8: 9-12.

Indexed at, Google Scholar, Crossref

3. Maroon JC, Bost JW, Borden MK, Lorenz KM, Ross NA, et al. (2006) Natural anti-inflammatory agents for pain relief in athletes. Neurosurg Focus 21:1-13.

Indexed at, Google Scholar, Crossref

4. Birnesser H, Oberbaum M, Klein P, Weiser M (2004) The Homeopathic Preparation Traumeel® S Compared With NSAIDs For Symptomatic Treatment Of Epicondylitis. J Musculoskelet Res 8: 119-128.

Indexed at, Google Scholar, Crossref

5. Gergianaki I, Bortoluzzi A, Bertsias G (2018) Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 32: 188-205.

Indexed at, Google Scholar, Crossref

6. Cunningham AA, Daszak P, Wood JLN (2017) One Health, emerging infectious diseases and wildlife: two decades of progress? Phil Trans 372: 1-8.

Indexed at, Google Scholar, Crossref

7. Sue LJ (2004) Zoonotic poxvirus infections in humans. Curr Opin Infect Dis MN 17: 81-90.

Indexed at, Google Scholar, Crossref

8. Pisarski K (2019) The global burden of disease of zoonotic parasitic diseases: top 5 contenders for priority consideration. Trop Med Infect Dis 4: 1-44.

Indexed at, Google Scholar, Crossref

9. Kahn LH (2006) Confronting zoonoses, linking human and veterinary medicine. Emerg Infect Dis 12: 556-561.

Indexed at, Google Scholar, Crossref

10. Bidaisee S, Macpherson CNL (2014) Zoonoses and one health: a review of the literature. J Parasitol 2014: 1-8.

Indexed at, Google Scholar, Crossref